Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's ...

By Rishika Sadam HYDERABAD (Reuters) -Demand for weight-loss drugs is rising at a fast clip in India where rivals Eli Lilly ...

Novo Nordisk and Eli Lilly are competing for the obesity-drug market, but their growth plans extend beyond weight-loss treatments. They face supply chain challenges, but both stocks show strong ...

Eli Lilly releases data for a new weight-loss drug to tackle obesity : Shots - Health News There's already a huge demand for existing weight-loss drugs, so the new medication is highly anticipated ...

A new drug from Eli Lilly & Co. appears to be a powerful weight-loss aid.If further studies can confirm it works and show that its effects last, health insurers should pay for the treatment.

Eli Lilly (LLY 0.82%) is doing the same with Mounjaro and Zepbound. ... Investors should keep their eyes on Roche; it could eventually be a formidable player in the obesity drug market.

Zinger Key Points. The global GLP-1 market is projected to reach $200 billion by 2031, with 68% from obesity drug sales. Novo Nordisk and Eli Lilly are expected to retain 66% of the market despite ...

Eli Lilly (LLY-2.55%) is working to capture as much of that market as it can, and it's probably going to succeed. Here's why. The juggernaut is picking up speed ...

Amgen (AMGN) and Pfizer (PFE) could soon be snacking on Novo Nordisk (NVO) and Eli Lilly's (LLY) lunch in the anti-obesity market, says Morningstar. Read more here.

Roche could be on track to claim a share of the obesity drug market down the road. Its forward price-to-earnings ratio of 15.6 is much lower than Eli Lilly's and Novo Nordisk's respective forward ...